Antibodies, ADCs and bispecifics highly sought in China deals

When biopharma companies in Europe and the U.S. look to China for innovative therapeutics deals, more often than not, it’s cancer technologies they’re seeking.

Using its BCIQ database, BioCentury analyzed the out-licensing deals and research partnerships announced from Jan. 1, 2013 to July 15, 2023, in which a Western company gained access to a Chinese company’s therapeutic candidate or technology, and found that 60% (103/172) of the deals with a disclosed disease focus area were cancer deals. ...